Rep. Lisa C. McClain Acquires Shares of ImmunityBio, Inc. (NASDAQ:IBRX)

Key Points

• Rep. Lisa C. McClain purchased between $1,001 and $15,000 of ImmunityBio shares on September 28, with the transaction disclosed October 12. She also reported another ImmunityBio purchase on September 30.
• ImmunityBio shares opened at $9.80, compared with a 52-week range of $1.95 to $12.43. The company’s latest quarterly results missed EPS expectations, though revenue exceeded forecasts.
• Analyst sentiment is mixed but leans positive: the stock has a consensus “Moderate Buy” rating and a $14.20 price target, while institutional ownership stands at 8.58% and insiders own 66.10%.

Representative Lisa C. McClain (Republican-Michigan) recently bought shares of ImmunityBio, Inc. (NASDAQ:IBRX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in ImmunityBio stock on September 28th. The trade occurred in the Representative's "CHARLES SCHWAB 401K (HANTZ) > SCHWAB 824" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 9/30/2026.
• Purchased $1,001 - $15,000 in shares of ImmunityBio NASDAQ: IBRX on 9/30/2026.
• Sold $15,001 - $50,000 in shares of Seagate Technology NASDAQ: STX on 9/30/2026.
• Purchased $1,001 - $15,000 in shares of Caterpillar NYSE: CAT on 9/28/2026.
• Purchased $15,001 - $50,000 in shares of Olin NYSE: OLN on 9/14/2026.
• Purchased $1,001 - $15,000 in shares of Novagold Resources NYSEAMERICAN: NG on 9/14/2026.
• Purchased $15,001 - $50,000 in shares of Transocean NYSE: RIG on 9/14/2026.
• Purchased $15,001 - $50,000 in shares of CACI International NYSE: CACI on 9/14/2026.

ImmunityBio Stock Performance

NASDAQ:IBRX opened at $9.80 on Wednesday. The stock's fifty day moving average is $8.43 and its 200 day moving average is $7.92. ImmunityBio, Inc. has a fifty-two week low of $1.95 and a fifty-two week high of $12.43. The firm has a market capitalization of $10.39 billion, a PE ratio of -10.10 and a beta of 0.02.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.14). The company had revenue of $51.24 million during the quarter, compared to the consensus estimate of $49.70 million. Equities analysts forecast that ImmunityBio, Inc. will post -0.44 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on IBRX. Jefferies Financial Group raised shares of ImmunityBio to a "strong-buy" rating in a research note on Friday, September 25th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ImmunityBio in a research note on Tuesday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.20.

Institutional Investors Weigh In On ImmunityBio

Hedge funds and other institutional investors have recently modified their holdings of the business. Courier Capital LLC boosted its holdings in ImmunityBio by 100.0% during the 3rd quarter. Courier Capital LLC now owns 112,000 shares of the company's stock valued at $1,057,000 after acquiring an additional 56,000 shares during the period. GAMMA Investing LLC increased its stake in ImmunityBio by 262.2% in the third quarter. GAMMA Investing LLC now owns 3,807 shares of the company's stock worth $36,000 after purchasing an additional 2,756 shares during the period. Collective Family Office LLC increased its stake in ImmunityBio by 2.6% in the third quarter. Collective Family Office LLC now owns 161,254 shares of the company's stock worth $1,522,000 after purchasing an additional 4,054 shares during the period. Doliver Advisors LP increased its stake in ImmunityBio by 110.0% in the third quarter. Doliver Advisors LP now owns 210,000 shares of the company's stock worth $1,982,000 after purchasing an additional 110,000 shares during the period. Finally, Envestnet Asset Management Inc. lifted its position in shares of ImmunityBio by 52.4% during the second quarter. Envestnet Asset Management Inc. now owns 27,659 shares of the company's stock worth $242,000 after purchasing an additional 9,513 shares during the last quarter. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Barry Simon sold 25,000 shares of the business's stock in a transaction on Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the sale, the director directly owned 2,777,788 shares of the company's stock, valued at approximately $29,861,221. The trade was a 0.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the company's stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $10.50, for a total transaction of $851,088.00. Following the completion of the transaction, the director owned 100,309 shares in the company, valued at approximately $1,053,244.50. The trade was a 44.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is currently owned by insiders.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About ImmunityBio

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body's immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.